Fax: (216) 444-3577
Challenges in the recruitment of adolescents and young adults to cancer clinical trials
Article first published online: 4 OCT 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 11, pages 2385–2393, 1 December 2007
How to Cite
Burke, M. E., Albritton, K. and Marina, N. (2007), Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer, 110: 2385–2393. doi: 10.1002/cncr.23060
- Issue published online: 19 NOV 2007
- Article first published online: 4 OCT 2007
- Manuscript Accepted: 12 JUN 2007
- Manuscript Revised: 8 JUN 2007
- Manuscript Received: 23 APR 2007
- 1Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005., .
- 5New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG), Pharmacology Group of the French Society of Paediatric Oncology (SFOP). European collaboration in trials of new agents for children with cancer. Eur J Cancer. 2004; 40: 1886–1892., , , ,
- 12Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. Bethesda, MD: National Cancer Institute; 2006;06-6067.
- 13Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. NIH Pub. No. 06-5767:1-14-173-190. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2006., , , .
- 14United States cancer incidence, mortality and survival: young adults are lagging further behind. Proc Am Soc Clin Oncol. 2002; 21: 389a., .
- 151999., , Coordinators. Enhancing accrual of adolescent and young adult cancer patients on clinical trials. NCI Workshop. Bethesda, MD, June 17,
- 31Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J Clin Oncol. 2005; 23: 4031–4038., , , et al.
- 32Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol. 1999; 17: 150–157., , , et al.
- 35Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007; 25: 247–256., , , et al.
- 38Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol. 1998; 16: 1287–1293., , , , , .
- 40Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized medical research Council/European organization for research and treatment of cancer study. J Clin Oncol. 1998; 16: 692–701., , , et al.
- 42Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004; 22: 2691–2700., , , et al.
- 43Adolescent cancers in the United States: a National Cancer Data Base (NCDB) report. J Pediatr Hematol Oncol. 1999; 21: 310., , , , , .
- 47Income, poverty, and health insurance coverage in the United States: 2004. U.S. Census Bureau, Current Population Reports, 2005. P60-229:16-21. Washington, DC: U.S. Census Bureau; 2005., , .
- 48Cure rates in Ewing tumor patients aged older than 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc Am Soc Clin Oncol. 2003; 22: 816a., , .